R&D
Technology to Increase Selectivity for
cancer cells and Enhance Efficacy
Pipeline
  • HOME
  • R&D
  • Pipeline
ADC Pipeline
Project/Target Indication Development Stage

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
 Antibody
Provider		 Licensee
ADC
platform
Pipeline		 PBX-CT01
(Undisclosed) 		Undisclosed
ADC
Products
Pipeline		 PBX-001
(Trop2) 		Triple Negative Breast Cancer (TNBC), lung cancer, bladder cancer, etc.
Sacituzumab
Biosimilar		 -
PBX-002
(Undisclosed) 		Triple Negative
Breast Cancer (TNBC), etc.
Undisclosed -
PBX-003
(EGFR) 		Colorectal cancer,
lung cancer,
head and neck cancer, etc.
-
Small Molecule Pipeline
Project Indication Development Stage

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
 Clinical Site
NTX-301 Solid tumor
- US Phase 1b/2a(ongoing)
- AUS Phase 1a(finished)
Hematological Malignancy
(MDS/AML/CMML)
- US Phase 1a(ongoing)
NTX-101 Glaucoma
- KR Phase 1(finished)